Mean (SD) change from baseline in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) activity score resulting from lenabasum treatment (IMAGE)

Elsevier

Mean (SD) change from baseline in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) activity score resulting from lenabasum treatment

Caption

Lenabasum 20 mg daily on Days 1-28, followed by lenabasum 20 mg BID on Days 29-84. *P-value = 2-sided, MMRM, lenabasum vs. placebo.

Credit

Werth VP, et al. Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial. J Invest Dermatol, https://doi.org/10.1016/j.jid.2022.03.029).

Usage Restrictions

Please include attribution.

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.